Status™ COVID-19/FLU

1 Test + 1 Specimen = 3 Results

Status™ COVID-19/FLU Product Image

TEST FOR LESS PROMO

StatusTM COVID-19/Flu, Buy 3 Kits and Get 1 FREE!

Preparing for the 2021-2022 Flu Season: What to Expect, and How to Plan Webinar

August 18, 2021 02:00 PM in Eastern Time (US and Canada)

REGISTER NOW
NACCHO Webinar Image

The only FDA EUA visual read rapid test for simultaneous detection and differential diagnosis of SARS-CoV-2, Influenza Type A & Influenza Type B Antigen in nasopharyngeal swab specimens.

Performance Characteristics

  • COVID-19: Sensitivity 93.9%; Specificity 100%
  • Flu A: Sensitivity 91.4%; Specificity 95.7%
  • Flu B: Sensitivity 87.6%; Specificity 95.9%

Efficient

  • 3 tests in 1 consolidates and speeds workflow
  • Fast results in only 15 minutes
  • Easy to run with no pipetting and premeasured buffer
  • Room temperature storage

Convenient

  • Generate revenue by processing results in-house
  • Visual read removes capital equipment analyzer costs
  • Collect 1 sample for both COVID-19, Flu A and Flu B
  • Simplified “Go Live” with Chembio’s enhanced on site training program

Test for SARS-CoV-2, Flu A & Flu B in 3 Easy Steps with Status™ COVID-19/Flu

Status Covid-19 Flu 3 Steps

Product Information*

Information Type Product Detail
Time to Results 15 Minutes
Sample Nasopharyngeal Swab Specimen
Reader No analyzer required; Visual Read
Storage Conditions 2 to 30°C (36 to 86°F)
Reimbursement COVID-19: 87811-QW
FLU A: 87804-QW
FLU B: 87804QW-59
Method Lateral Flow

Product Downloads & Links

Please fill out the form below to receive product materials.

Ordering Information

Product # of Tests Catalog Number
StatusTM COVID-19/Flu 25 90-2021-3

*This test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories; This test has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.” Under the drop downs at the bottom of the page.